TipRanks on MSN

Zenas BioPharma says obexelimab met primary endpoint in Phase 3 INDIGO trial

Zenas BioPharma (ZBIO) announce results from the Phase 3 INDIGO trial of obexelimab in Immunoglobulin G4-Related Disease. Obexelimab met the ...
The Manila Times

Zenas BioPharma Announces Positive Results from Phase 3 INDIGO Registrational Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD)

Obexelimab met the primary endpoint demonstrating a clinically meaningful and highly statistically significant 56% reduction ...
Business Wire

Vertex to Present Phase 3 Data Highlighting Suzetrigine’s Potential as a First-in-Class, Highly Selective Pain Signal Inhibitor at the American Society of Anesthesiologists ...

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the company will present its pivotal Phase 3 data on suzetrigine, an investigational, oral, highly ...
Fierce Pharma

Neurocrine's Ingrezza fails phase 3 trial for cerebral palsy

Just days after an upbeat R&D event, Neurocrine Biosciences has found itself having to report a phase 3 failure. | Neurocrine’s Ingrezza, approved to treat certain uncontrolled movements, failed to ...
Nasdaq

Reviva Pharmaceuticals Reports Completion of Brilaroxazine Long-Term OLE Trial and Upcoming Phase 3 RECOVER-2 Trial Initiation

Reviva Pharmaceuticals Holdings, Inc. announced that 446 participants have completed their long-term open-label extension (OLE) trial for brilaroxazine, with 156 participants receiving one year of ...
Business Wire

Compass Pathways Successfully Achieves Primary Endpoint in First Phase 3 Trial Evaluating COMP360 Psilocybin for Treatment-Resistant Depression

“The positive top-line results at week 6 from the COMP005 trial underscore the innovative potential of psilocybin treatment in mental health care for which Compass Pathways continues to pave the way,” ...
Seeking Alpha

aTyr Pharma: Estimating Their Phase 3 Lung Disease Trial Outcome

aTyr Pharma is a small-cap biotech focused on Efzofitimod for interstitial lung disease (ILD), a group of lung-scarring diseases. In 2021, the company completed a phase 1b/2a trial in pulmonary ...
Aviation Week

ULA Anticipated Winning 40% Share Of NSSL Phase 3 Awards, CEO Says

ULA's Vulcan first-stage booster at Cape Canaveral Space Force Station. Credit: United Launch Alliance COLORADO SPRINGS—Given price competition from SpaceX, United Launch Alliance (ULA) expected to ...
Nasdaq

Valneva and Pfizer Report Further Positive Phase 2 Booster Results for Lyme Disease Vaccine Candidate

VLA15-221 Phase 2 study: strong immune response shown one month after a second booster dose (month 31) in pediatric and adult populations Significant anamnestic antibody response observed across all ...
Aviation Week

Space Force Reopens NSSL Phase 3 Lane 1 To New Providers

Blue Origin’s New Glenn rocket at liftoff during the NG-2 mission on Nov. 13. Credit: Blue Origin The U.S. Space Force is now taking proposals from new launch providers with rockets ready to fly by ...
Morningstar

Compass Pathways Successfully Achieves Primary Endpoint in First Phase 3 Trial Evaluating COMP360 Psilocybin for Treatment-Resistant Depression

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced today the successful achievement of the primary endpoint ...